Although none of the reported NPs for the delivery of RES in the AD and PD treatment used specific molecular and cellular targets for these diseases, some targeting moieties can be explored such as α-synuclein protein, the parkin protein and leucine-rich repeat serine/threonine protein kinase 2 for PD, and α-, β-, and γ-synuclein peptides for AD (Garbayo et al., 2013). This evidence concerns the gene PRKN and Parkinson disease.